Idera Pharmaceuticals, Inc. (IDRA) And The Myositis Association Join Forces To Advance The Clinical Development Of A Novel TLR Antagonist, IMO-8400, For The Treatment Of Myositis
8/7/2014 10:37:11 AM
CAMBRIDGE, Mass. & ALEXANDRIA, Va.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism. Under the collaboration, Idera and TMA will develop educational programs and resources for patients and healthcare providers, including interactive online chats, on TLR antagonism and opportunities to participate in upcoming clinical research. Idera plans to initiate a clinical trial of its investigational drug candidate IMO-8400, a first-in-class antagonist of TLRs 7, 8 and 9, in polymyositis and dermatomyositis by the end of 2014.
Help employers find you! Check out all the jobs and post your resume
comments powered by